Disclosed herein are systems and method for treating a patient. In one embodiment, disclosed is a method of treating a patient, including the steps of identifying a patient who has undergone a bariatric surgical procedure; and positioning a gastrointestinal sleeve device with a proximal end, distal end, and elongate body in a patient such that the proximal end of the sleeve device is positioned in the stomach and the distal end of the sleeve device is positioned in the intestine. The proximal end of the sleeve can be positioned in the native stomach or a neo-stomach, in some embodiments. The bariatric surgical procedure can be, for example, a Roux-en-Y gastric bypass, sleeve gastrectomy, sleeve gastrectomy with duodenal switch, biliopancreatic diversion, biliopancreatic diversion with duodenal switch, vertical banded gastroplasty, vertical banded gastroplasty with gastric bypass, Lap-Band procedure, or Magenstrasse and Mill procedure. In some embodiments, the method further includes the step of securing the proximal end of the gastrointestinal sleeve with respect to the neo-stomach. In some embodiments, the gastrointestinal sleeve device is operably attached to a proximal attachment element at the proximal end of the sleeve device. Securing the proximal end of the gastrointestinal sleeve can involve either penetratingly or nonpenetratingly attaching the sleeve device through a wall of the neo-stomach. The proximal attachment element could include any number of features, for example, an attachment cuff, an expandable dome, an outwardly-biased funnel, a stent, an expandable structure, a balloon, or woven shape memory material in some embodiments. In some embodiments, the step of positioning the distal end of the sleeve device within the intestine involves. toposcopically everting the sleeve within the intestine. In some embodiments, the method includes the step of leaving the gastrointestinal sleeve device within the patient for at least about 2 weeks. In some embodiments, positioning the distal end of the sleeve device within the intestine involves positioning the distal end of the sleeve device within the duodenum, jejunum, or the ileum. Positioning the sleeve device can occur in the same operative session as the bariatric surgical procedure, or an operative session at a later date.
In some embodiments, disclosed herein is a method of treating a patient, including the steps of identifying a patient who has undergone a bariatric surgical procedure; and positioning a gastrointestinal sleeve device with a proximal end, distal end, and elongate body in a patient such that the proximal end of the sleeve device is positioned in the stomach and the distal end of the sleeve device is positioned in the intestine.
In some embodiments, disclosed is a method of treating a patient, including the steps of identifying a patient who has undergone a bariatric surgical procedure; and positioning a gastrointestinal sleeve device in a patient such that the proximal end of the sleeve device is positioned at the gastroesophageal junction and the distal end of the sleeve device is positioned in the intestine.
In some embodiments, disclosed is a method of treating a patient, including the steps of identifying a patient who has undergone a bariatric surgical procedure; and positioning a gastrointestinal sleeve device in a patient such that the proximal end of the sleeve device is positioned at the gastroesophageal junction and the distal end of the sleeve device is positioned in the stomach to create a restrictive effect.
In some embodiments, disclosed is a method of treating a patient, including the steps of providing a gastrointestinal sleeve device, the sleeve device comprising one or more fins configured to radially expand from the sleeve device against the greater curvature of the stomach; positioning the gastrointestinal sleeve device in the patient such that the fins radially expand against the greater curvature of the stomach; and stapling the stomach to perform a sleeve gastrectomy such that the fins are captured in the resulting staple line, securing the fins within the neo-stomach created by the sleeve gastrectomy.
Bariatric surgery procedures to induce weight loss, such as in morbidly obese patients for example, include, for example, the Roux-en-Y gastric bypass, sleeve gastrectomy (SG), sleeve gastrectomy with duodenal switch (SG-DS) or biliopancreatic diversion (BPD), vertical banded gastroplasty (VBG), VBG with bypass (VBG-GB), Magenstrasse and Mill procedure, and adjustable gastric banding (AGB). Bariatric surgical procedures generally seek to promote weight loss through at least one of two mechanisms: (1) creating a restrictive effect (e.g., by reducing the effective volume of the stomach) and/or (2) creating a malabsorptive effect (e.g., by creating an intestinal bypass).
The normal native stomach anatomy is shown in
A common result of all these bariatric surgical procedures is that they leave a residual stomach or “neo-stomach” that is a remnant portion of the natural stomach. The size of the neo-stomach varies by procedure and physician, but can be no more than about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% or less of the volume of the native stomach. Surgeons create the neo-stomach by suturing or stapling off a small portion of the stomach near the GEJ and then often severing this connection to the bypassed portion of the stomach. In cases where there is a bypassed portion of the stomach, it is left in the patient. When there is a completely sectioned off portion such as in the sleeve gastrectomy procedure, the excised portion is removed.
With all of these aforementioned bariatric surgery procedures, there are a certain percentage that do not have acceptable outcomes. This can be caused by a number of reasons. Endoscopic examination or other followup diagnostic studies such as barium swallow, CT scan, or MRI can show that the neo-stomach has undesirably expanded, the presence of a fistula leading out of the neo-stomach, and/or the length of the bypass may not be sufficient. In any of these cases, while referred to as an endoscopic bypass sleeve the sleeve could be implanted surgically, laparoscopically, or more preferably endoscopically in some embodiments to accomplish additional weight loss using any of the delivery techniques previously disclosed in the applications previously incorporated by reference, such as, for example. If necessary, the EBS could have modifications or attachments as will be disclosed to address other issues relating to the changes in the post-surgical anatomy. The endoscopic bypass sleeve (also referred to herein as the EBS or bypass sleeve) can be, in some embodiments, a generally tubular sleeve that could be used, in some embodiments, either (1) as an adjunct at the time of the initial bariatric surgical procedure, to create a restriction or a gastric and partial intestinal bypass; or (2) as a re-do procedure after the initial bariatric surgical procedure for patients that have experienced an unacceptable or suboptimal clinical result, to create a restriction, restore a restriction, or to create or lengthen a partial intestinal bypass. Some non-limiting examples of potential uses for a bypass sleeve concurrent with or following a bariatric surgical procedure are listed in the table below.
If the anastomosis has dilated, the EBS could have a stoma that returns the size of the anastomosis to its desired dimension. The stoma could be located anywhere along the length of the EBS as has been previously described.
If neo-stomach is dilated or expanded, the EBS could have a volume occupying component that will reside in the neo-stomach. This could be, for example, an implant such as an inflatable balloon, expandable mesh, or bezoar type device, such as, e.g., on the outside of the sleeve that can reduce the effective volume of the neo-stomach and induce a sensation of satiety.
In a redo procedure, the size of the proximal anastomosis from the previous bariatric surgery can vary considerably. Because of this, the EBS could come in a variety of sizes to fit the variable anatomy encountered in the procedure. Typical proximal diameters for the EBS could be, in some embodiments, at least about 5 mm to no more than about 50 mm, more preferably at least about 10 mm and no more than about 40 mm. The proximal end would be most preferably sized in some embodiments to fit the neo-stomach or gastroesophageal junction (GEJ) where it will be placed and the sleeve diameter can be selected based on the size of the anastomosis at the time of the procedure. In some embodiments, these two components could be separate pieces that are selected from a range of sizes and fit together during the procedure. Means to connect the proximal end and the sleeve could include snap fit connections, press fit connections, suturing, clipping, stapling, quick setting adhesives or epoxies, thermal bonding, crimping, etc.
Alternatively, the sleeve diameter does not have to be constant throughout the length of the sleeve based on the diameter of the anastomosis diameter. Between the proximal end of the sleeve and the rest of the length of the sleeve could be a neck portion that is sized to fit the anastomosis. If the anastomosis has not dilated much since surgery, it could be less than about 5 cm, 4 cm, 3 cm, 2 cm, 1 cm, or less in diameter. As an example, in one embodiment the proximal end may be 30 mm in diameter, taper down to 10 mm in diameter then expand back to 20 mm in diameter.
The orientation of the anastomosis can vary and should not be considered a limitation for placement of the EBS. The proximal anastomosis, known as the gastro-jejunal or GJ anastomosis, can be side-to-side, end-to-side, or end-to-end. If desired, the EBS need not be a substantially linear tube and could have variations either in the form of curves or elbows along its length to accommodate for these variations. This could occur for example if the proximal end is implanted in the GEJ and then needs to make a sharp turn to go through a side-to-side anastomosis in the neo-stomach connecting to the intestine.
One example of a patient who could benefit from a bypass sleeve as an adjunct to bariatric surgery is a patient has a RYGB and has good results initially including significant excess weight loss. At a certain time, such as 6, 12, or 18 months or more or less the patient begins to regain weight and experience increased hunger. Endoscopic examination shows that the neo-stomach is enlarged and the proximal anastomosis has also expanded. The decision is made to implant an EBS. The EBS, in one embodiment, preferably has a proximal, or top portion that is preferably configured to expand to a greater diameter than the proximal anastomosis, such as at least about 100%, 125%, 150%, 175%, 200%, or more of the diameter of the proximal anastomosis. The proximal portion could be made of a shape memory material such as nitinol, elgiloy, or a polymer, and/or plastic, silicone or other materials, or other materials depending on the desired clinical result in some embodiments. The proximal portion could be a solid structure, a mesh structure, woven, braided or a stent in some embodiments. After the proximal portion which can be made of shape memory material, for example, the rest of the EBS is a bypass sleeve as described in prior applications, but is approximately between about 50-200 cm long in some embodiments, between about 10-20 mm in diameter, such as about 15 mm in diameter, and preferably has a hydrophilic outer coating, such as the HARMONY coating from Surmodics in some embodiments.
In some embodiments, a gastrointestinal bypass sleeve is proximally attached to a portion of, for example, the esophagus, the gastroesophageal junction, the stomach, or neo-stomach in order to prevent undesired migration of the bypass sleeve. Various non-limiting examples of attachment embodiments will be described in connection with
A method for implanting a bypass sleeve 100 within a patient is disclosed and illustrated in
The delivery catheter 400 is advanced perorally into the neo-stomach 160 and cannulates the GJ anastomosis 152, as illustrated in
The delivery catheter 400 is then retracted into the neo-stomach 160 as illustrated in
Other various ways can be used to attach the proximal end of the bypass sleeve to the desired location. These include: T-tags, sutures, adhesives, such as PMMA, cyanoacrylate, or fibrin glue; stents, such as cylindrical or conical shaped stents or z-stents; barbs, shape memory funnels, shape memory gasket or baffle elements, that may be dome-shaped in some embodiments, balloons, expandable mesh structures such as woven or braided nitinol, elgiloy or plastics that can be optionally coated with a material such as silicone, polyurethane, ePTFE, or PTFE. The proximal end can also include an intragastric support sized to fit the neostomach. Various possible attachment options are described in
In many cases the neo-stomach has much less motility than a normal stomach, and so attachment to this area may be able to use devices that would not work effectively in unmodified (native) anatomy.
In some embodiments, the bypass sleeve may be implanted in the patient for at least about 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, or more depending on the desired clinical result. In some embodiments, the bypass sleeve may be switched out after any time period for a longer or shorter bypass sleeve if clinically indicated.
So far, what has been described primarily has been attaching the bypass sleeve 100 in the neo-stomach 160 above the proximal anastomosis 152. The bypass sleeve 100 could also be attached at the top of or above the neo-stomach 160 at or near the GEJ 162 using any of the described attachment methods. This may be determined based on the size of the neo-stomach 160 at the time of the redo procedure. If the neo-stomach 160 has dilated since the initial bariatric procedure, placement of the proximal end of the bypass sleeve higher (more proximal) in the neo-stomach 160 or at the GEJ 162 would reduce the volume by partitioning the neo-stomach 160 to serve to create a smaller volume.
In addition, in some embodiments, the bypass sleeve 100 could be deployed below the proximal anastomosis 152, for example, in the proximal part of the ROUX Limb 150.
Note that in a sleeve gastrectomy, since there is no anastomosis, the preferred location in some embodiments, for attachment would be at or near the GEJ 162, but could be placed further down (distally) in the neo-stomach 160 in other embodiments.
The length of the bypass sleeve 100 could be varied either for a desired length or to have a desired placement relative to the anatomy. For example, it may be beneficial to have the length of the sleeve 100 less than the distance to the distal anastomosis, known as the jejunaljejunal or JJ anastomosis, greater than that length or equal to that length, depending on if it is desired to adjust the location where the food contents in the sleeve mix with the bilio-pancreatic secretions coming out of the duodenum and bypassed portion of the stomach.
At the time of surgery, the size of the neo-stomach varies depending on the procedure:
RYGB—typically the volume is 20-30 ml and the size of the GJ (proximal) anastomosis is 10 mm
SG—the diameter of the sleeve is typically created by placing a tube into the stomach and using that as a mandrel to create the sleeve and target the staple line. The typical diameter of the tube used is 10-15 mm. The resulting neo-stomach is in the range of 30% or less of the normal stomach.
Some estimates indicate that 20-30% of AGB patients do not achieve satisfactory weight loss. Many of these patients will go on to have a more invasive procedure such as the Roux-en-Y gastric bypass. The sleeve device could be used in conjunction with one or more gastric bands. The band would be left in place and forms a stoma at the GEJ. The bypass sleeve would be deployed in the stomach and intestine as described previously. The proximal part of the sleeve would be attached just above the stomach, in the ways described previously. In the way, the adjustable feature of the gastric band could still be used, altering the stoma size as needed.
Sleeve material and embodiments, for example, can be as described in previous disclosures, such as disclosed in the Kagan '892 publication, for example, at
Thus far described herein is placing the bypass sleeve in a mode of revisional or failed primary bariatric surgery. The device as described herein and in related applications could, in some embodiments, be placed either at the time of bariatric surgery in any of the procedures described or at a later time if results with the primary procedure are not satisfactory.
If the bypass sleeve is deployed at the time of surgery when an intestinal bypass is constructed, it could be done either perorally or operatively during the procedure. In a RYGB or VBG-GB, the bypass sleeve could be deployed into the ROUX limb before it is connected to the neo-stomach.
If placed during the procedure the bypass sleeve could be used to create a longer section of bypassed intestine. For instance, if the physician desired in a RYGB or VBG-GB to bypass 150 cm of intestine, they could create the physical bypass via the surgery at 75 cm and then place a 75 cm EBS at the proximal anastomosis as shown in
While the present application describes various sleeve lengths and features in the context of certain bariatric surgical procedures, the sleeve can be of any desired length depending on the desired clinical result. For example, in some embodiments, the sleeve when positioned can extend proximally from the esophagus or GEJ distally to the duodenum, jejunum, ileum, or colon, or any between any other two locations within the GI tract. The sleeve may, in some embodiments, have an axial length of at least about 20 cm, 30 cm, 40 cm, 50 cm, 75 cm, 100 cm, 125 cm, 150 cm, 175 cm, 200 cm, 225 cm, 250 cm, 275 cm, 300 cm, 350 cm, 400 cm, 450 cm, 500 cm, 550 cm, 600 cm, 700 cm, 800 cm, 900 cm, or more. In other embodiments, the sleeve may have an axial length of no more than about 900 cm, 800 cm, 700 cm, 600 cm, 550 cm, 500 cm, 450 cm, 400 cm, 350 cm, 300 cm, 275 cm, 250 cm, 225 cm, 200 cm, 175 cm, 150 cm, 125 cm, 100 cm, 75 cm, 50 cm, 40 cm, 30 cm, 20 cm, or less.
The bypass sleeve may be delivered toposcopically as described elsewhere in the application. In some embodiments, the sleeve can be delivered toposcopically as described in U.S. patent application Ser. No. 11/861,156 entitled TOPOSCOPIC ACCESS AND DELIVERY DEVICES, filed Sep. 25, 2007, and hereby incorporated by reference in its entirety. The proximal end of the sleeve may be secured to the stomach or esophagus, such as the GEJ as described, using both transmural and non-transmural attachment methods as described, for example, in connection with
Common Nutritional Deficiencies are:
Hyperparathyroidism, due to inadequate absorption of calcium, may occur in a large number, such as over 30% of GBP patients. Calcium is primarily absorbed in the duodenum, which is bypassed by the surgery. Most patients can achieve adequate calcium absorption by supplementation with Vitamin D and Calcium Citrate (carbonate may not be absorbed—it requires an acidic stomach, which is bypassed).
Iron frequently is seriously deficient, particularly in menstruating females, and should be supplemented. Again, iron is normally absorbed in the duodenum. Ferrous sulfate can cause considerable GI distress in typically prescribed doses; alternatives include ferrous fumarate, ferrous gluconate, or a chelated form of iron. Occasionally, a female patient develops severe anemia, even with supplements, and must be treated with parenteral iron.
Vitamin B-12 requires intrinsic factor from the gastric mucosa to be absorbed. In patients with a small gastric pouch, it may not be absorbed, even if supplemented orally, and deficiencies can result in pernicious anemia and neuropathies. Sub-lingual B-12 appears to be adequately absorbed.
Thiamine deficiency (also known as beriberi) will, rarely, occur as the result of its absorption site in the jejunum being bypassed. This deficiency can also result from inadequate nutritional supplements being taken post operatively.
Protein malnutrition is a significant risk in patients post-bariatric surgery. Some patients suffer troublesome vomiting after surgery, until their GI tract adjusts to the changes, and cannot eat adequate amounts even with several meals a day. Many patients require protein supplementation during the early phases of rapid weight loss, or even parenteral nutrition, to prevent excessive loss of muscle mass.
Note that if so desired the bypass sleeve could be used to replace the intestinal bypass or create one, while the neo-stomach is still created with a surgical technique. An example would be in the SG. In this procedure a neo-stomach approximately 30% of the volume of the native stomach is created, but here there is no intestinal bypass. By placing the bypass sleeve either in the neo-stomach or at the GEJ the procedure would have the added benefit of an intestinal bypass without the permanent alteration to the anatomy. An intestinal bypass is illustrated in FIG. 16 of the Kagan '148 application and FIG. 1A of the Kagan '634 application, incorporated by reference as noted above. One particular example of a bypass sleeve to replace an intestinal bypass, where the neo-stomach is still created using a surgical technique is described below.
Bypass Sleeve Placement as Alternative to Biliopancreatic Diversion with or without Duodenal Switch following Sleeve Gastrectomy
The sleeve gastrectomy, Magenstrasse and Mill procedure, or other procedure such as those described and illustrated above may be followed by a second stage procedure, such as a biliopancreatic diversion (BPD) with or without duodenal switch (DS or BPD-DS), typically 6-12 months following the sleeve gastrectomy procedure. The delay prior to the second stage procedure can allow the physician a period of time to evaluate the patient's clinical course following the first bariatric surgical procedure and determine if a second intervention is indicated to promote additional weight loss.
Anatomy of the gastrointestinal tract following sleeve gastrectomy is shown in
A biliopancreatic diversion procedure without duodenal switch (BPD, also known as the Scopinaro procedure) is illustrated in
In contrast to the Scopinaro BPD procedure, the DS procedure keeps the pyloric valve intact. As shown in
The malabsorptive element of the DS requires that those who undergo the procedure take vitamin and mineral supplements above and beyond that of the normal population, as do patients having the Roux-en-Y surgery. Commonly prescribed supplements include a daily prenatal and vitamin and extra calcium citrate. However, the duodenal switch procedure bypasses a greater proportion of the intestine than the RNY procedure described above and thus allows for considerably less absorption, and thus potential weight loss.
Because gallstones are a common complication of rapid weight loss following any type of weight loss surgery, some surgeons may remove the gallbladder as a preventative measure during the DS or the RNY. Others will retain the gallbladder, and prefer to prescribe medication (e.g., ursodiol) to reduce the risk of post-operative gallstones. In addition to nutritional deficiencies caused by malabsoprtion, potential complications of a BPD with or without DS procedure include anastomostic failure causing leaks, infection, perforation, venous thrombo-phlebitis, ulcers, adhesions, and stomal stenosis.
These complications may be minimized or avoided by an implantable sleeve such as described above that can functionally recreate a BPD-DS. A schematic of a sleeve functionally recreating a DS, shown delivered within the GI tract, according to one embodiment of the invention, is shown in
Because the DS switch procedure bypasses a greater proportion of the intestine than the RNY and thus allows for considerably less absorption as noted above, it is generally desirable to use a sleeve having a greater length than a sleeve configured for placement after RNY. A RNY sleeve, in some embodiments, typically has its distal end positioned within the jejunum, at least about 350 cm, 400 cm, 450 cm, 500 cm, 600 cm, 700 cm, or more in a proximal direction with respect to the cecal valve. In contrast, for such a sleeve being implanted to replicate a DS, in some embodiments, the proximal end of the sleeve is secured within the esophagus or stomach, such as at the GEJ, and the distal end of the sleeve is positioned within the ileum, approximately no more than about 200 cm, 175 cm, 150 cm, 125 cm, 100 cm, 75 cm, 50 cm, 40 cm, 30 cm, or less in a proximal direction with respect to the cecal valve. Depending on the desired clinical result, the sleeve could later be replaced by another sleeve of either shorter or longer length to adjust the length of the common channel, and thus the amount of food absorption.
Bypass Sleeve Placement Concurrent with Sleeve Gastrectomy
In some embodiments, a sleeve as previously described could be designed specifically for use for placement concurrently with a bariatric surgical procedure, such as sleeve gastrectomy. This may involve the sleeve having expandable or self expanding components such as stents, flanges, rings or other structures made out of, for example, superelastic material. In one embodiment, as shown in
The fins 89 could be made out of a variety of materials. They could be made out of, for example, PTFE, ePTFE, polyurethane, silicone or a variety of materials that are currently used for buttressing staple lines. These buttress materials are commonly used to help prevent leaks along a staple line in surgical procedures, especially in bariatric surgery and can be made by synthetic materials or using biologically-based materials such as pericardial tissue, small intestinal submucosa (SIS), or collagen. This way, the fin 89 may serve a dual purpose of holding the sleeve 100 in place and also helping ensure against staple line leaks.
In some embodiments, the fins 89 would be collapsible for sleeve delivery then expand after delivery of the sleeve or could be released by the operator by actuating a control element. The control element could be as simple as a suture that is wrapped around the fin holding it flat against the previously described delivery catheter. The control suture would hold the fins flat with knots that release when pulled with the control suture.
In some embodiments, the sleeve 100 could have additional structural components to help its function, including a proximal opening with some reinforcement to help keep it in proper alignment to catch incoming food or liquids. This could be any one of the many designs of a cuff with some hoop strength that have been disclosed in previous applications incorporated by reference herein for use at the GEJ with a sleeve. This could include an elastic ring or band at the proximal sleeve opening made from superelastic material or silicone.
A method of deploying a sleeve 100 including one or more fins 89 during a sleeve gastrectomy procedure is described. The sleeve 100 is placed over the delivery catheter so the most distal edge of the most distal fin 89 is proximal of the distal end of the delivery catheter. The sleeve 100 is then inverted into the delivery catheter as previously described. An overtube can then be deployed. Next, the delivery catheter with the sleeve 100 is placed into the pylorus and the sleeve is deployed into the intestine, such as toposcopically as previously described. The fin 89 is then released, expanding radially into the stomach 110 and oriented towards the greater curve 84 of the stomach 110. In some embodiments there are indicia inside the delivery catheter so by placing an endoscope into the delivery catheter the proper position and/or orientation of the fins 89 within the stomach 110 can be confirmed. Alternatively there could be indicia made on the proximal end of the delivery catheter or overtube so by observing the indicia outside of the patient's mouth the operator can confirm the positioning and alignment of the fins 89. The delivery catheter is left at the pylorus for the sleeve gastrectomy. The delivery catheter would serve as the bougie, which is a tube often used in sleeve gastrectomy procedures to size the diameter of the sleeve 100 the surgical procedure will create.
The surgeon then resects the stomach with staples as is currently done in sleeve gastrectomy. The staple line captures the fins of the sleeve holding it the sleeve in place. The sleeve is then released from the delivery catheter and the delivery catheter is removed leaving the sleeve in place.
In some embodiments, the sleeve and fin can be disconnected from the staple line at a later time with an endoscope so that the sleeve could be removed at a later point in time if the desired weight loss is achieved or there is resolution of comorbidities that are intended to be treated, such as diabetes.
While this invention has been particularly shown and described with references to embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention. For all of the embodiments described above, the steps of the methods need not be performed sequentially. While any above-listed applications may have been incorporated by reference for particular subject matter as described earlier in this application, Applicants intend the entire disclosures of the above-identified applications to be incorporated by reference into the present application, in that any and all of the disclosures in these incorporated by reference applications may be combined and incorporated with the embodiments described in the present application.
The present application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/943,014, filed Jun. 8, 2007, and U.S. Provisional Application No. 60/982,692 filed Nov. 25, 2007, both of which are hereby incorporated by reference in their entireties. Various features of, for example, gastrointestinal bypass sleeves, attachment cuffs, and/or toposcopic delivery methods that can be used or adapted for use with systems and methods disclosed herein can be found, for example, at U.S. patent application Ser. No. 10/698,148, filed Oct. 31, 2003, published May 13, 2004 as U.S. Patent Pub. No. 2004-0092892 A1 and entitled “APPARATUS AND METHODS FOR TREATMENT OF MORBID OBESITY” (and may be referred to herein as the “Kagan '148 application or Kagan '892 publication”); U.S. patent application Ser. No. 11/025,364, filed Dec. 29, 2004, published Aug. 11, 2005 as U.S. Patent Pub. No. 2005-0177181 A1 and entitled “DEVICES AND METHODS FOR TREATING MORBID OBESITY” (and may be referred to herein as the “Kagan '181 publication”); U.S. patent application Ser. No. 11/124,634, filed May 5, 2005, published Jan. 26, 2006 as U.S. Patent Pub. No. 2006-0020247 A1 and entitled “DEVICES AND METHODS FOR ATTACHMENT OF AN ENDOLUMENAL GASTROINTESTINAL IMPLANT” (and may be referred to herein as the “Kagan '247 publication”); U.S. patent application Ser. No. 11/400,724, filed Apr. 7, 2006, published Jan. 11, 2007 as U.S. Patent Pub. No. 2007-0010794 A1 and entitled “DEVICES AND METHODS FOR ENDOLUMENAL GASTROINTESTINAL BYPASS” (and may be referred to herein as the “Dann '794 publication”); and U.S. patent application Ser. No. 11/548,605, filed Oct. 11, 2006, published Aug. 23, 2007 as U.S. Pub. No. 2007-0198074 A1 and entitled “DEVICES AND METHODS FOR ENDOLUMENAL GASTROINTESTINAL BYPASS” (and may be referred to herein as the “Dann '605 application” or “Dann '074 publication”); and U.S. Provisional Application No. 60/943,014 filed Jun. 8, 2007 and entitled “GASTROINTESTINAL BYPASS SLEEVE AS AN ADJUNCT TO BARIATRIC SURGERY” are hereby incorporated by reference in their entireties herein, as well as any additional applications, patents, or publications noted in the specification below.
Number | Date | Country | |
---|---|---|---|
60943014 | Jun 2007 | US | |
60982692 | Oct 2007 | US |